Pasithea Therapeutics Corp. ((KTTA)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pasithea Therapeutics Corp. is conducting a Phase 1 clinical trial titled A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition. The study aims to evaluate the safety and side effects of PAS-004 in patients with specific genetic mutations linked to advanced solid tumors.
The intervention being tested is PAS-004, a MEK 1/2 inhibitor, administered orally in capsule and tablet forms. The treatment is designed to target and inhibit specific pathways in cancer cells, potentially offering a new therapeutic option for patients with these mutations.
This interventional study is non-randomized and follows a sequential model with no masking. It uses a 3+3 dose expansion design to determine the optimal dosage for treatment, with the primary purpose being treatment evaluation.
The study began on February 12, 2024, with the last update submitted on August 15, 2025. These dates mark the study’s progress and ongoing recruitment status, which is crucial for tracking its development and potential outcomes.
For investors, the progress of this study could influence Pasithea Therapeutics’ stock performance, as successful results may enhance the company’s market position. The study’s focus on a novel treatment approach may also affect investor sentiment positively, especially in comparison to competitors in the oncology sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.